Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Authors:
Open Access
- 27 April 2019
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 38 (8) , 2233-2239
Abstract
Lowering serum urate levels below the threshold for crystal formation with urate-lowering therapy (ULT) has been associated with a lower risk for gout flare reoccurrences. However, gout patients on ULT still commonly suffer from recurring gout flares. The purpose of this study was to explore prognostic factors associated with gout flare recurrence within the first 3 months, in gout patients starting ULT during an acute gout flare. Post-hoc analysis of trial data on acute gout patients randomized to either gout flare standard of care or anakinra treatment were used, including baseline demographic, laboratory, clinical, and patient-reported variables, as well as 3-month follow-up data on gout flare recurrences. Only patients starting ULT at baseline were included. Using variable selection based on clinical relevance, univariate, and multivariate binary logistic regression analyses were done to examine predictors of gout flare reoccurrence. A total of 75 patients were included in this study, of which 36 (48%) experienced a gout flare ≤ 3 months post baseline. The multivariate regression analysis revealed that CRP levels > 30 mg/L (OR 9.47) and lack of prophylaxis when starting ULT (OR 11.56) were independently associated with gout flare recurrence. Similar results were found for the univariate regression analyses. Our results show that CRP levels > 30 mg/L and lack of prophylaxis when starting ULT were prognostic factors for early gout flare reoccurrence in patients starting ULT during an acute gout flare.Keywords
Funding Information
- ZonMw (836031015)
- Swedish Orphan Biovitrum AB (n/a)
This publication has 32 references indexed in Scilit:
- Gout: why is this curable disease so seldom cured?Annals of the Rheumatic Diseases, 2012
- 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care & Research, 2012
- Rilonacept (interleukin‐1 trap) for prevention of gout flares during initiation of uric acid–lowering therapy: Results from a phase III randomized, double‐blind, placebo‐controlled, confirmatory efficacy studyArthritis Care & Research, 2012
- Health related quality of life among adolescents with premenstrual disorders: a cross sectional studyHealth and Quality of Life Outcomes, 2012
- Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised studyAnnals of the Rheumatic Diseases, 2011
- Gout treatment and comorbidities: a retrospective cohort study in a large US managed care populationBMC Musculoskeletal Disorders, 2011
- Effect of Prophylaxis on Gout Flares After the Initiation of Urate-Lowering Therapy: Analysis of Data From Three Phase III TrialsClinical Therapeutics, 2010
- Work productivity loss due to flares in patients with chronic gout refractory to conventional therapyJournal of Medical Economics, 2010
- The Effect of Serum Urate on Gout Flares and Their Associated CostsJCR: Journal of Clinical Rheumatology, 2009
- Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005Annals of the Rheumatic Diseases, 2008